Form 4: ResMed Counsel Sells Shares Under 10b5-1 Plan

Michael J. Rider, ResMed's Global General Counsel, reported the sale of 100 shares of common stock on October 1, 2025, executed under a Rule 10b5-1 trading plan.

Summary

• Michael J. Rider, Global General Counsel of ResMed Inc. (RMD), reported a transaction involving company stock.
• On October 1, 2025, Rider disposed of 100 shares of ResMed Common Stock.
• The shares were sold at a price of $274.36 per share.
• Following this transaction, Rider beneficially owns 11,327 shares of ResMed Common Stock directly.
• The transaction was conducted pursuant to a Rule 10b5-1 plan adopted on February 28, 2025.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned insider sale under a 10b5-1 plan, which is generally considered a neutral event as it does not typically signal new information about the company's prospects.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a scheduled sale rather than a reaction to new, non-public information.

Negatives

• A sale of company stock by an insider, even if pre-planned, reduces their direct ownership stake in the company.

Future Outlook

NA

Industry Context

This Form 4 filing reports a routine insider stock transaction and does not contain information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but mitigated by the pre-planned nature of the sale under a Rule 10b5-1 plan.

Key Dates

Keywords

ResMed, RMD, Insider Trading, Form 4, Stock Sale, Michael J. Rider, 10b5-1 Plan, Corporate Governance